Read what our Authors have to say about publishing in our Journal
Journal Name: Current Enzyme Inhibition
✔ 120+ Journals
✔ 7 Book Series
✔ 45 Books in Total
♦ Access to over 12,000 scholarly articles covering several aspects of diabetes
♦ Contents come from more than 100 Bentham Science Journals
♦ Includes both; Original Research and Review Articles
♦ Research from leading institutions in USA, EUROPE, AUSTRALIA, JAPAN, CHINA and other regions
♦ Suitable for researchers in industry and academia wishing to keep updated with latest developments
♦ Easy access to institutions and individuals through IP-based authentication
♦ Access new Diabetes Research included in this collection as soon as it is published
Over 500 articles from 2018 |
Over 1,400 articles from the last 3 years |
More than 5,000 articles from the last 10 years |
Annual addition of over 500 Diabetes related articles each year
Tailor-made packages available for pharmaceuticals companies, research institutes, universities, hospitals, clinical/academic societies, and corporations.
You can also send your librarian’s contact information to us at marketing@benthamscience.net CC: hermain@benthamscience.net
Current Enzyme Inhibition aims to publish original research, review and letter articles in all the latest and outstanding developments on enzyme inhibition studies. The coverage includes the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Current Enzyme Inhibition is an essential journal for every pharmaceutical researcher and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.
For details on the articles, please visit this link: https://bit.ly/2GvzmfU
Journal: Current Enzyme Inhibition
Author(s): Romana Parveen, Tooba Naz Shamsi, Sumbul Afreen, Mudsser Azam, Tasneem Fatma, Qazi Mohd. Rizwanul Haque, Sadaf Fatima*
Background: Trypsin Inhibitors are one of the most promising and investigated subject for their role in pharmacognostical and pharmacological studies.
Aim: The paper describes purification and characterization of trypsin inhibitor obtained from blackeyed cowpea (Vigna unguiculata).
Methods: The purification procedure of Vigna unguiculata trypsin inhibitor (VUTI) includes homogenization followed by ammonium sulphate precipitation. The protein thus precipitated was further dialysed and purified by ion exchange chromatography and gel permeation chromatography. The molecular weight was determined by SDS-PAGE. The protein thus purified was characterized biochemically to demonstrate curative potential as strong antioxidant, anti-inflammatory and antimicrobial agent.
Results: The 15 kDa VUTI obtained showed IC50 values 490 µg/ml compared to standard which was 254µg/ml in 1, 1-diphenyl-2-picrylhydrazyl (DPPH) assay. Also, the highest ferric reducing antioxidant power (FRAP) results confirmed the highest FRAP value of 0.405 mM at 1000 µg/ml and the lowest value of 0.113 mM at 100 μg/ml which were quite comparable to ascorbic acid (standard). Anti-inflammatory activity of VUTI was depicted by the method of inhibition of albumin denaturation where, VUTI showed high IC50 value of 696.46 µg/ml. Also, VUTI showed good antibacterial potential by inhibiting all tested bacterial strains with maximum inhibition against Bacillus subtilis (99.62%) and minimum against Staphylococcus aureus (34.62%). The results were quite comparable with standard drug ampicillin (5 mg/ml). Unfortunately, VUTI failed to show any activity against fungi.
Conclusion: Thus, the results obtained depict that VUTI additionally be a wonderful candidate for development of novel antibacterial drugs, and it can also be used to reduce the deletorious effects of free radicals.
Read more here: http://www.eurekaselect.com/153396/article
Current Enzyme Inhibition aims to publish original research, review and letter articles in all the latest and outstanding developments on enzyme inhibition studies. The coverage includes the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Current Enzyme Inhibition is an essential journal for every pharmaceutical researcher and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.
For details on the articles, please visit this link :: http://bit.ly/2nrdtEV
You must be logged in to post a comment.